Bohemine
Cat. No.：YN350125
CAS No. ：189232-42-6
| 产品名称: | Bohemine |
| CAS No.: | 189232-42-6 |
| Chemical Name: | 3-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-propanol |
| Synonyms: | 1-Propanol,3-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-;3-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]propan-1-ol;BOHEMINE;2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine;2-[(3-hydroxypropyl)amino]-6-benzylamino-9-isopr |
| 分子量: | 340.42 |
| 分子式: | C₁₈H₂₄N₆O |
| SMILES: | OCCCNC1=NC(NCC2=CC=CC=C2)=C3N=CN(C(C)C)C3=N1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Bohemine 是一种嘌呤类似物，也是一种合成的选择性的CDK抑制剂，对Cdk2/cyclin E，Cdk2/cyclin A和Cdk9/cyclin T1的IC50分别为 4.6 μM，83 μM 和 2.7 μM。Bohemine 还抑制ERK2，IC50为 52 μM，对 CDK1，CDK4 和 CDK6 的抑制作用较小。Bohemine 具有广泛的抗癌活性。 |
| IC50和靶点: | [{name:"CDK2/cyclinE:4.6 μM (IC50)"},{name: "cdk2/cyclin A:83 μM (IC50)"},{name: "CDK9/cyclinT1:2.7 μM (IC50)"},{name: "ERK2:52 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Raynaud, F.I., Whittaker, S.R., Fischer, P.M., et al.In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202Clin. Cancer Res.11(13),4875-4887(2005)
Francěk, F., Strnad, M., Havlíček, L., et al.Diverse effects of the cyclin-dependent kinase inhibitor bohemine: Concentration- and time-dependent suppression or stimulation of hybridoma cultureCytotechnology36(1-3),117-123(2001)
